BTK and B-cell chronic lymphocytic leukemia: Namely, it has been observed in vivo in the mouse models of CLL where BTK inhibitor ibrutinib and anti-ROR1 antibody (Yu et al., 2017b) or casein kinase 1 (CK1) inhibitors (Janovska et al., 2018) showed synergistic effects.